Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development expenses	$ 4,352,987	$ 3,687,999	$ 13,275,947	$ 7,865,249
General and administrative expenses	2,926,209	3,274,325	9,575,122	7,252,371
Total operating expenses	7,279,196	6,962,324	22,851,069	15,117,620
Loss from operations	(7,279,196)	(6,962,324)	(22,851,069)	(15,117,620)
Interest (expenses) income, net:
Interest (expense) income, net	(145,254)	1,358	(65,008)	2,617
Loss before income taxes	(7,424,450)	(6,960,966)	(22,916,077)	(15,115,003)
Benefit from income taxes	0	0	1,198,905	4,516,488
Net loss	(7,424,450)	(6,960,966)	(21,717,172)	(10,598,515)
Comprehensive loss	$ (7,424,450)	$ (6,960,966)	$ (21,717,172)	$ (10,598,515)
Per share information:
Net loss per share, basic (in dollars per share)	$ (0.26)	$ (0.24)	$ (0.76)	$ (0.43)
Net loss per share, diluted (in dollars per share)	$ (0.26)	$ (0.24)	$ (0.76)	$ (0.43)
Weighted average common shares outstanding, basic (in shares)	28,458,688	28,425,850	28,452,997	24,639,299
Weighted average common shares outstanding, diluted (in shares)	28,458,688	28,425,850	28,452,997	24,639,299